Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac
Phase 3positiveLivmarliPositive
AI Analysis
Summary
Mirum Pharmaceuticals announced positive Phase 3 trial results for Livmarli, showing the ileal bile acid transporter inhibitor significantly reduced cholestatic pruritus versus placebo in patients with cholestatic liver diseases including biliary atresia.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus placebo in patients with cholestatic liver diseases
Importance:8/10
Sentiment:
0.85
rare diseaseliver diseasePhase 3 successbiliary atresiacholestatic pruritus
Related Companies
Read the original article
Published by Endpoints News on October 12, 2026 3:12 PM